Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 206
- Registration Number
- NCT01204593
- Locations
- 🇩🇿
Investigational Site Number 01202, Algiers, Algeria
🇦🇷Investigational Site Number 03201, Caba, Argentina
🇿🇦Investigational Site Number 12468, Benoni, South Africa
ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2012-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 40
- Registration Number
- NCT01204580
- Locations
- 🇮🇩
Sanofi-Aventis Administrative Office, Jakarta, Indonesia
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 207
- Registration Number
- NCT01203111
- Locations
- 🇻🇪
Administrative office, Caracas, Venezuela
Apidra Children & Adolescents Study
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2010-09-15
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT01202474
- Locations
- 🇷🇺
Administrative office, Moscow, Russian Federation
Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 154
- Registration Number
- NCT01199081
- Locations
- 🇨🇿
Investigational Site Number 203001, Praha 2, Czech Republic
🇫🇷Investigational Site Number 250-003, Chambray Les Tours Cedex, France
🇩🇪Investigational Site Number 276-002, Chemnitz, Germany
Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Placebo (for Dronedarone)
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 76
- Registration Number
- NCT01198873
- Locations
- 🇺🇸
Investigational Site Number 840031, Ocala, Florida, United States
🇺🇸Investigational Site Number 840051, St Petersburg, Florida, United States
🇺🇸Investigational Site Number 840102, St. Louis, Missouri, United States
Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine (HOE901)
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2011-10-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT01195454
- Locations
- 🇩🇪
Sanofi-Aventis Administrative Office, Berlin, Germany
Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: HUMAN INSULIN (BIOSYNTHETIC)Drug: Insuplant
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 479
- Registration Number
- NCT01194882
- Locations
- 🇫🇷
Investigational Site Number 250-005, Paris, France
🇫🇷Investigational Site Number 250-004, Corbeil Essonnes, France
🇸🇪Investigational Site Number 752-001, Stockholm, Sweden
Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
- Conditions
- Neoplasms, Malignant
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 39
- Registration Number
- NCT01193595
- Locations
- 🇮🇹
Investigational Site Number 380002, Milano, Italy
🇮🇹Investigational Site Number 380001, Milano, Italy
🇫🇷Investigational Site Number 250001, Villejuif Cedex, France
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Device: Pen auto-injectorDevice: Pre-filled pen injector
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 148
- Registration Number
- NCT01175473
- Locations
- 🇩🇪
Sanofi-Aventis Investigational Site Number 276004, Kiel, Germany
🇩🇪Sanofi-Aventis Investigational Site Number 276002, Mainz, Germany
🇩🇪Sanofi-Aventis Investigational Site Number 276006, Berlin, Germany